Core Viewpoint - Ensurge Micropower ASA is conducting a Subsequent Offering of up to 22,222,222 new shares at a subscription price of NOK 0.90 per share, aimed at providing an opportunity for shareholders who did not participate in the previous Private Placement [1][2]. Group 1: Offering Details - The Subscription Period for the Subsequent Offering ends on 12 December 2025 at 16:30 CET [2]. - Shareholders who did not participate in the Private Placement on 9 November 2025 can subscribe for Offer Shares at the same price as in the Private Placement [2]. - Completed subscription forms must be received by designated managers or registered online before the end of the Subscription Period [3]. Group 2: Company Overview - Ensurge Micropower specializes in advanced microbattery technology, focusing on AI-enabled devices, and is based in San Jose, California [5]. - The company utilizes high-precision roll-to-roll production processes for its thin-film batteries, enabling applications across consumer, medical, and industrial markets [5]. - Ensurge partners with leading global customers to accelerate product market entry and is listed on the Oslo Stock Exchange [5].

Core Viewpoint - The company has decided not to proceed with the Subsequent Offering due to the trading performance of its shares, which have remained at or below the subscription price from the Private Placement for an extended period [2][3]. Group 1 - The board of directors resolved to cancel the Subsequent Offering [2]. - The cancellation is attributed to the company's shares trading at or below the subscription price for a significant duration and volume [3]. - Shareholders have had the opportunity to mitigate the dilutive impact of the Private Placement by purchasing shares in the market at prices equal to or lower than the proposed subscription price for the Subsequent Offering [3].

Core Viewpoint - Ensurge Micropower ASA has successfully completed a private placement of 111,111,111 new shares and is launching a subsequent offering of up to 22,222,222 new shares at a subscription price of NOK 0.90 per share, equal to the price in the private placement [1][2]. Group 1: Private Placement and Subsequent Offering - The private placement was announced on 9 November 2025, and the subsequent offering was approved by the Extraordinary General Meeting on 3 December 2025 [1]. - The subsequent offering will issue shares with a nominal value of NOK 0.50, and the subscription period runs from 5 December 2025 to 12 December 2025 [2][3]. Group 2: Subscription Rights and Eligibility - Subscription rights will be allocated to shareholders who held shares on 7 November 2025 and were not allocated shares in the private placement [4]. - Eligible shareholders will receive 0.042889 subscription rights per share held, with each right allowing the subscription for one offer share [5]. Group 3: Subscription Process and Timeline - Subscription rights must be exercised before the expiration of the subscription period on 12 December 2025, after which they will lapse without value [6]. - Oversubscription is permitted, and the payment for the offer shares is expected around 17 December 2025, with delivery anticipated on or about 22 December 2025 [7]. Group 4: Company Overview - Ensurge Micropower specializes in advanced microbattery technology for AI-enabled devices, focusing on thin-film batteries produced through high-precision roll-to-roll processes [9]. - The company partners with global customers to accelerate product market entry and is listed on the Oslo Stock Exchange [9].

Core Points - Hofseth BioCare ASA ("HBC" or "the Company") is conducting a Subsequent Offering of up to 16,666,666 new shares at a subscription price of NOK 1.80 per share [2][5] - The Subscription Period for the Offering will expire on 20 November 2025 at 16:30 hours (CET) [3] - Unused subscription rights will lapse without compensation after the Subscription Period [3] Offering Details - The subscription forms must be correctly completed and received by DNB Carnegie before the expiry of the Subscription Period [4] - The Company has published a national prospectus in accordance with the Norwegian Securities Trading Act, which is available on its website [5] Contact Information - For further inquiries, Jon Olav Ødegård, CEO at HBC, can be contacted via phone or email [6]

Core Points - The company Hofseth Biocare ASA (HBC) is proceeding with a Subsequent Offering of up to 16,666,666 new Ordinary Shares, aiming to raise approximately NOK 30 million [2][3] - Eligible shareholders will receive non-transferable subscription rights, allowing them to subscribe for one Offer Share for each 0.1134 existing share held as of the Record Date [4] - The subscription period for the Subsequent Offering is set from 10 November 2025 to 20 November 2025 [5] Offering Details - The Subsequent Offering is conditional upon necessary corporate resolutions being passed, including an extraordinary general meeting on 20 November 2025 [7] - The due date for payment for the Offer Shares is expected to be on 26 November 2025, with shares becoming listed on Euronext Oslo Børs around 2 December 2025 [6] - Over-subscription is permitted, and any remaining Offer Shares may be allocated to strategic investors at the Board's discretion [3][5] Legal and Regulatory Information - A national prospectus will be published in accordance with the Norwegian Securities Trading Act, and it will be available on the company's website prior to the subscription period [6] - The announcement is not an offer to sell or a solicitation to purchase any securities and is subject to specific legal restrictions in certain jurisdictions [10][15]

Core Viewpoint - Hofseth BioCare ASA ("HBC" or "the Company") is conducting a Subsequent Offering to raise gross proceeds of approximately NOK 30 million by issuing up to 16,666,666 new shares at a subscription price of NOK 1.80 per share, which is the same as the offer price in the recent Private Placement [2][3]. Subsequent Offering Details - The Subsequent Offering is conditional upon the approval of the Company's extraordinary general meeting (EGM) scheduled for around 20 November 2025, which will authorize the board of directors to issue shares [3][4]. - The offering is directed towards shareholders as of 24 October 2025, excluding those who participated in the Private Placement and those in jurisdictions where the offering would be unlawful [4]. - If Eligible Shareholders do not subscribe for all available shares, remaining shares may be allocated to Secondary Subscribers deemed strategically important by the Board [4][5]. - The subscription period will begin following the publication of an offering prospectus, and the Company reserves the right to cancel the offering if the shares trade at or below the offer price in significant volumes [5][6]. Important Dates and Information - Date of approval for the Subsequent Offering: On or about 20 November 2025 [4]. - Last day including right: 24 October 2025 [6]. - Ex-date: 27 October 2025 [6]. - Record date: 28 October 2025 [6]. - Maximum number of new shares to be issued: 16,666,666 [6]. - Subscription price per share: NOK 1.80 [6].

Core Viewpoint - Hofseth BioCare ASA ("HBC" or "the Company") is conducting a Subsequent Offering to raise gross proceeds of approximately NOK 30 million by issuing up to 16,666,666 new shares at a subscription price of NOK 1.80 per share, which is the same as the offer price in the recent Private Placement [2][3]. Subsequent Offering Details - The Subsequent Offering is conditional upon the approval of the Company's extraordinary general meeting (EGM) scheduled for around 20 November 2025, which will authorize the board of directors to issue shares [3][4]. - The offering is directed towards shareholders as of 24 October 2025, excluding those who participated in the Private Placement and those in jurisdictions where the offering would be unlawful [4]. - If Eligible Shareholders do not subscribe for all available shares, remaining shares may be allocated to Secondary Subscribers deemed strategically important by the board [4][5]. - The subscription period will begin following the publication of an offering prospectus, and the Company reserves the right to cancel the offering if the shares trade at or below the offer price in significant volumes [5][6]. Important Dates and Information - Date of approval for the Subsequent Offering: On or about 20 November 2025 [4]. - Last day including right: 24 October 2025 [6]. - Ex-date: 27 October 2025 [6]. - Record date: 28 October 2025 [6]. - Maximum number of new shares to be issued: 16,666,666 [6]. - Subscription price per share: NOK 1.80 [6].

Core Viewpoint - Kaldvik AS is conducting a Subsequent Offering of up to 4,300,000 new shares at a subscription price of NOK 14 per share, aiming to raise gross proceeds of NOK 60,200,000 [2][3]. Offering Details - The subscription period for the Subsequent Offering starts on 2 September 2025 and ends on 16 September 2025 [4]. - The offering is available to shareholders as of 4 June 2025 who meet specific eligibility criteria [5]. - Eligible shareholders will receive 0.16865 Subscription Rights for each existing share held, allowing them to subscribe for new shares at the set price [5]. Subscription Rights and Procedures - Over-subscription and subscription without Subscription Rights are not permitted [6]. - Subscription Rights must be exercised before the expiry of the Subscription Period, or they will lapse without value [8]. - Payment for the Offer Shares is due on 19 September 2025, with trading expected to commence on Euronext Growth Oslo shortly thereafter [9]. Management and Legal Advisory - DNB Carnegie, Arion banki hf., and Nordea Bank Abp are acting as managers for the Subsequent Offering, with Advokatfirmaet Thommessen AS providing legal advice [10].

Core Viewpoint - Kaldvík AS has completed a private placement and is considering a subsequent offering for eligible shareholders who were not included in the private placement [2][3][4] Group 1: Private Placement Details - The private placement was announced on 5 June 2025, with a maximum of 4.3 million new shares to be issued at a subscription price of NOK 14 per share [3] - The last day to receive subscription rights was 4 June 2025, with the record date set for 6 June 2025 [3] - The approval for the subsequent offering is expected around 19 June 2025, pending necessary corporate resolutions [3] Group 2: Eligibility and Conditions - Eligible shareholders include those who were not part of the pre-sounding phase or allocated shares in the private placement, and who reside in jurisdictions where the offering is lawful [2][3] - No oversubscriptions will be allowed, and subscription rights will not be tradable [3] Group 3: Role of Financial Institutions - DNB Carnegie acts as the Sole Global Coordinator and Joint Bookrunner, with Arion Banki hf and Nordea Bank Abp also serving as Joint Bookrunners for the private placement and potential subsequent offering [5]

Core Viewpoint - Kaldvik AS is planning a private placement to raise approximately EUR 46.2 million through the issuance of new shares, which is part of a refinancing package to support its operations and financial obligations [2][4]. Group 1: Private Placement Details - The private placement aims to raise gross proceeds of approximately EUR 46.2 million, with an offer price set at NOK 14 per share [2]. - The placement will be divided into two tranches, with Tranche 1 consisting of 5,976,172 shares, and Tranche 2 will include additional shares necessary to meet the total gross proceeds [7]. - The application period for the private placement starts on June 4, 2025, and ends on June 5, 2025, with the company reserving the right to modify the application period [6]. Group 2: Use of Proceeds - The net proceeds from the private placement, along with new debt financing, will be utilized for biomass build-up, repayment of a bridge facility, shareholder loans, and general corporate purposes [4]. Group 3: Investor Commitments - The largest shareholder, Austur Holding AS, which owns 57.46% of the shares, has committed to subscribe for shares in the private placement [8]. - Other investors, including Laxar Eignarhaldsfelag ehf and Eskja Holding ehf, have also committed to subscribe for their pro-rata shares [8]. Group 4: Regulatory and Compliance Aspects - The private placement will be directed towards Norwegian and international investors, adhering to relevant exemptions from registration and prospectus requirements [11]. - The company has considered equal treatment obligations under Norwegian law and believes the transaction structure complies with these requirements [13]. Group 5: Timeline and Settlement - Settlement for Tranche 1 is expected around June 10, 2025, while Tranche 2 is anticipated to settle around June 23, 2025, subject to approval by an extraordinary general meeting [10].